

**ASCLETIS PHARMA INCORPORATED:**  
**MANAGEMENT MAY DREAM OF GREATNESS,**  
**BUT THE DREAMS MAY NOT BE TRANSLATED INTO REALITY**

With regard to prospective investors, obtaining meaningful dividends from Ascletis Pharma Incorporated () (Code: 1672, Main Board, The Stock Exchange of Hongkong Ltd), it would be, simply put, but a figment of one's imagination.

In the view of this medium, investing in this Company by purchasing some of its shares, one is more than likely to experience extended periods of drought long before material profits could be forthcoming.

And dividends may only be paid out of profits.

In short, by making a determination to invest in Ascletis Pharma Incorporated, one should be fully prepared for long periods of famine before the first smell of a feast.

By the way, the name of this Company, '*Ascletis*' Pharma Incorporated, appears to have been derived from the Greek word, '*Asclepius*', who was said to have been the son of Apollo. Asclepius is described in Greek mythology as being a hero and a god of healing.

Apollo, a god, was said to have been the son of Zeus and Leto in Greek mythology and was claimed to have been associated with music, poetic inspiration, archery, prophecy, medicine, pastoral life, and the sun.

**The Initial Public Offering (IPO) Of Ascletis Pharma Incorporated**

On July 20, 2018, Management of Ascleitis Pharma Incorporated unleashed its Global Offering Prospectus in the Hongkong Special Administrative Region (HKSAR) of the People's Republic of China (PRC).

The Company Offered a total of 224,137,000, \$US0.0001 Shares at the Indicative Offer Price Per Share, ranging from a low of \$HK12.00 to a high of \$HK16.00.

The IPO stated that investors of the HKSAR were Offered the opportunity to subscribe to 22,414,000 Shares and International Investors – Institutions, Professional Investors and/or qualified, Well-Heeled Individuals – were Offered 201,723,000 Shares.

At the midpoint of the Indicative Offer Price Per Share, being \$HK14.00, the Company estimated that it would net about \$HK2,976,000,000.00.

Last Tuesday, Management announced that, in fact, the Offer Price Per Share had been struck at \$HK14.00 and that, indeed, the estimated net proceeds from the IPO would come in at about \$HK2,976,000,000.00.

This very material amount of money, the Global Offering Prospectus stated at Pages 271 and 272, with concurrence in respect of last Tuesday's announcement as to the Offer Price Per Share and the Allotment Results, are destined to be allocated to the following purposes:

- Approximately, 30 percent of the net proceeds, derived from this IPO, that is about \$HK892.80 million, *'will be used for the continued research and development of our Core Product\* pipeline'*;
- Approximately, 25 percent of the net proceeds, derived from this IPO, that is about \$HK744.00 million, *'will be used for commercialisation of Ganovo\* and ravidasvir\*'*;
- Approximately, 15 percent of the net proceeds, derived from this IPO, that is about \$HK446.40 million, *'will be used for pursuing in-licensing of new drug candidates; although we have not identified any specific targets as of the Latest Practicable Date (July 12, 2018)'*;
- Approximately, 10 percent of the net proceeds, derived from this IPO, that is about \$HK297.60 million, *'will be used for research and development of ASC21\* by initiating and conducting clinical trials'*;
- Approximately, 10 percent of the net proceeds, derived from this IPO, that is about \$HK297.60 million, *'will be used for supporting our research and development infrastructure and the early development of our two in-house drug programs at discovery stage for HBV\* and NASH\*'*; and,
- Approximately, 10 percent of the net proceeds, derived from this IPO, that is about \$HK297.60 million, *'will be used for our working capital and other general corporate purposes'* ... ... [CLICK TO ORDER FULL ARTICLE](#)

***While TARGET makes every attempt to ensure accuracy of all data published,  
TARGET cannot be held responsible for any errors and/or omissions.***

*If readers feel that they would like to voice their opinions about that which they have read in **TARGET**, please feel free to e-mail your views to [editor@targetnewspapers.com](mailto:editor@targetnewspapers.com). **TARGET** does not guarantee to publish readers' views, but reserves the right so to do subject to the laws of libel.*